BSX Boston Scientific Corp

  1. Stocks
  2. Healthcare
  3. NYSE: BSX

Price (delayed)

$74.92

Market cap

$110.15B

P/E Ratio

62.43

Dividend/share

N/A

EPS

$1.2

Enterprise value

$118.44B

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, ...

Highlights
The EPS has soared by 103% YoY and by 11% from the previous quarter
Boston Scientific's net income has surged by 97% YoY and by 11% QoQ
Boston Scientific's debt has increased by 18% YoY and by 17% QoQ
Sector: Healthcare
Industry: Medical Devices
Website: https://www.bostonscientific.com/
Peers: EW SYK MMSI MDT

Key stats

What are the main financial stats of BSX
Market
Shares outstanding
1.47B
Market cap
$110.15B
Enterprise value
$118.44B
Valuations
Price to earnings (P/E)
62.43
Price to book (P/B)
5.52
Price to sales (P/S)
7.48
EV/EBIT
48.94
EV/EBITDA
32.58
EV/Sales
8.05
Earnings
Revenue
$14.71B
EBIT
$2.42B
EBITDA
$3.64B
Free cash flow
$1.73B
Per share
EPS
$1.2
Free cash flow per share
$1.18
Book value per share
$13.58
Revenue per share
$10.02
TBVPS
$11.22
Balance sheet
Total assets
$36.67B
Total liabilities
$16.5B
Debt
$10.62B
Equity
$19.93B
Working capital
$3.27B
Liquidity
Debt to equity
0.53
Current ratio
1.66
Quick ratio
0.94
Net debt/EBITDA
2.28
Margins
EBITDA margin
24.7%
Gross margin
69.3%
Net margin
12.1%
Operating margin
16.7%
Efficiency
Return on assets
5.1%
Return on equity
9.3%
Return on invested capital
13.1%
Return on capital employed
7.6%
Return on sales
16.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BSX stock price

How has the Boston Scientific stock price performed over time
Intraday
0.89%
1 week
-3.4%
1 month
-2.83%
1 year
42.98%
YTD
29.6%
QTD
-2.71%

Financial performance

How have Boston Scientific's revenue and profit performed over time
Revenue
$14.71B
Gross profit
$10.19B
Operating income
$2.46B
Net income
$1.77B
Gross margin
69.3%
Net margin
12.1%
Boston Scientific's net income has surged by 97% YoY and by 11% QoQ
Boston Scientific's net margin has surged by 75% YoY and by 8% QoQ
Boston Scientific's operating income has increased by 42% YoY and by 5% from the previous quarter
BSX's operating margin is up by 26% year-on-year

Growth

What is Boston Scientific's growth rate over time

Valuation

What is Boston Scientific stock price valuation
BSX P/E details
P/E
62.43
P/B
5.52
P/S
7.48
EV/EBIT
48.94
EV/EBITDA
32.58
EV/Sales
8.05
The EPS has soared by 103% YoY and by 11% from the previous quarter
The P/E is 14% below the 5-year quarterly average of 72.8 and 6% below the last 4 quarters average of 66.3
The stock's price to book (P/B) is 42% more than its 5-year quarterly average of 3.9 and 25% more than its last 4 quarters average of 4.4
The equity has grown by 12% YoY and by 3.3% from the previous quarter
BSX's P/S is 41% above its 5-year quarterly average of 5.3 and 23% above its last 4 quarters average of 6.1
The revenue has increased by 13% YoY and by 3.3% from the previous quarter

Efficiency

How efficient is Boston Scientific business performance
The return on assets has surged by 96% year-on-year and by 11% since the previous quarter
The return on equity has surged by 94% year-on-year and by 9% since the previous quarter
BSX's ROIC is up by 38% YoY and by 4.8% from the previous quarter
The ROS has increased by 28% YoY and by 4.4% from the previous quarter

Dividends

What is BSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BSX.

Financial health

How did Boston Scientific financials performed over time
Boston Scientific's total assets is 122% more than its total liabilities
BSX's quick ratio is up by 49% since the previous quarter and by 45% year-on-year
BSX's current ratio is up by 26% since the previous quarter and by 19% year-on-year
Boston Scientific's debt is 47% lower than its equity
Boston Scientific's debt has increased by 18% YoY and by 17% QoQ
Boston Scientific's debt to equity has increased by 13% from the previous quarter and by 6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.